




RealRate

PHARMACEUTICAL 2026

Filana Therapeutics INC
Rank 93 of 178



The relative strengths and weaknesses of Filana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Filana Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Filana Therapeutics INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 220%, being 8.9% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	97,709
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	43,834
Liabilities, Non-Current	118
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	4,417
Other Revenues	0
Property and Equipment	20,646
Research and Development	26,590
Selling, General and Administrative Expense	68,800

Output Variable	Value in 1000 USD
Assets	118,355
Liabilities	43,952
Expenses	95,390
Revenues	0
Stockholders Equity	74,403
Net Income	-90,973
Comprehensive Net Income	-90,973
BaseVar	131,057
ECR before LimitedLiability	88%
Economic Capital Ratio	220%